Fbxo3 Inhibitor, BC-1215

A cell-permeable, bis-pyridinylbenzylethanamine that disrupts Fbxo3-Fbxl2 interaction by targeting Fbxo3 C-terminal ApaG domain and effectively prevents SCF-Fbxo3-catalyzed Fbxl2 ubiquitination, resulting in upregulation of cellular Fbxl2 and thereby SCF-Fbxl2-catalyzed ubiquitination of TRAFs (TNF Receptor-Associated Factors). Effectively reduces cellular TRAFs in human macrophage U937, PBMC, and murine murine MLE cultures (16 to 18 h with 5 to 127 µM BC-1215), resulting in downregulation of TRAF-mediated cytokines production from LPS-stimulated human PBMC (2 µg/mL LPS; 25 µM BC-1215;16 h). Intraperitoneal injection in mice in vivo (100 µg/mouse) is shown to greatly prevent circulating proinflammatory cytokines increase post CLP (Cecal Ligation & Puncture) and substantially reduce the severity of cell infiltration in lung after intratracheal P. aeruginosa PA103 infection.

Cell permeable: yes

Primary Target
Fbox3

Reversible: yes

Packaged under inert gas

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Chen, B.B., et al. 2013. Nat. Immunol.14, 470.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Standard Handling (A)